瑞典13,099例代谢功能障碍相关脂肪性肝病患者的死因别死亡率
基于瑞典2002-2020年住院或专科门诊登记的13,099例MASLD患者与118,884名匹配对照的全国性队列研究显示,MASLD患者全因死亡风险升高(HR 1.85,95%CI 1.74-1.96),除精神健康障碍外各死因死亡率均升高,肝相关及HCC相关死亡关联最强,但15年累积死亡发生率最高者为非HCC癌症和心血管疾病。
要点
- MASLD患者全因死亡风险约为对照的1.85倍(HR 1.85,95%CI 1.74-1.96)。
- 非HCC肝相关死亡HR 26.9(95%CI 19.4-37.3),HCC相关死亡HR 35.0(95%CI 17.0-72.1),关联最强。
- MASLD患者15年累积死亡发生率最高者为非HCC癌症7.3%和心血管疾病7.2%。
核心结论
- MASLD与肝相关及HCC相关死亡强关联,但绝对死亡风险最高者为非HCC癌症和心血管疾病。
- MASLD患者几乎所有死因的死亡率均升高,提示可能需要更早的多学科照护以降低超额死亡。
研究设计与样本
- 基于瑞典医疗登记的人口基础队列研究,纳入2002-2020年住院或专科门诊有MASLD的ICD-10编码者13,099例,按年龄、性别、市镇和日历年匹配最多10名(中位9名)普通人群对照118,884名。
- 采用Cox回归估计11种主要死因的校正风险比(HR)及95%CI,并在考虑竞争风险下计算15年累积死亡发生率。
主要发现
- 中位随访MASLD患者4.7年(IQR 2.0-9.2)、对照5.8年(IQR 2.7-10.5)期间,MASLD组死亡1,628例(12.4%),对照组死亡9,119例(7.7%)。
- MASLD与更高的全因死亡率相关(HR 1.85,95%CI 1.74-1.96),除精神健康障碍外所有特定死因死亡率均更高。
- 关联最强者为非HCC肝相关死亡(HR 26.9,95%CI 19.4-37.3)和HCC相关死亡(HR 35.0,95%CI 17.0-72.1)。
- MASLD患者15年累积死亡发生率最高者为非HCC癌症(7.3%)和心血管疾病(7.2%)。
关键数值与推荐
- 全因死亡:MASLD组vs对照组HR 1.85(95%CI 1.74-1.96)。
- 非HCC肝相关死亡:HR 26.9(95%CI 19.4-37.3);HCC相关死亡:HR 35.0(95%CI 17.0-72.1)。
- MASLD患者15年累积死亡发生率:非HCC癌症7.3%,心血管疾病7.2%。
临床怎么用
- 研究绝对死亡风险估计可能有助于临床医生和决策者告知患者预后,并可能实施临床或公共卫生策略以降低过早死亡。
- 作者认为可能需要更早的多学科照护以降低MASLD患者的过早死亡。
局限性
- 既往研究样本小、仅限肝相关死亡、依赖肝活检识别患者(因此引入选择偏倚)或主要使用旧队列数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Data on cause-specific mortality in metabolic dysfunction-associated steatotic liver disease (MASLD) are limited. We aimed to determine the rate and risk of death from different causes in patients with MASLD compared to the general population in Sweden. METHODS: In this population-based cohort study, we identified individuals with an ICD-10 code for MASLD in inpatient or specialized outpatient care using Swedish healthcare registers from 2002-2020 (n = 13,099) and matched them with up to 10 controls (median 9) from the general population for age, sex, municipality, and calendar year (n = 118,884). We used Cox regression to estimate adjusted hazard ratios (HRs) and 95% CIs for 11 different primary causes of death. 15-year cumulative incidences of death were calculated while accounting for competing risks. RESULTS: In total, 1,628 (12.4%) deaths occurred in patients with MASLD and 9,119 (7.7%) in controls during a median follow-up of 4.7 (IQR 2.0-9.2) and 5.8 years (IQR 2.7-10.5), respectively. MASLD was associated with higher all-cause mortality (HR 1.85, 95% CI 1.74-1.96) and higher rates of all specific causes of death except mental health disorder. The strongest associations were observed for non-hepatocellular carcinoma (HCC) liver-related (HR 26.9, 95% CI 19.4-37.3) and HCC-related (HR 35.0, 95% CI 17.0-72.1) mortality. However, the highest estimated 15-year cumulative incidences of death in patients with MASLD were for non-HCC cancer (7.3%) and cardiovascular disease (7.2%). CONCLUSIONS: MASLD was strongly associated with liver- and HCC-related mortality, but the absolute risks of death were highest for non-HCC cancer and cardiovascular disease. Mortality was increased for nearly all causes in patients with MASLD, suggesting that earlier multidisciplinary care is needed to reduce excess mortality. IMPACT AND IMPLICATIONS: Previous studies on mortality in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) were either small, restricted to liver-related mortality, relied on liver biopsy to identify patients (thus inducing selection bias), or mainly used data from old cohorts. In a nationwide cohort study of all patients diagnosed with MASLD in inpatient or specialized outpatient care in Sweden between 2002 and 2020, we found a nearly doubled all-cause mortality rate and higher mortality than the general population from a wide range of causes, indicating that earlier multidisciplinary care may be needed to reduce premature mortality in patients with MASLD. The absolute risk estimates of death in our study may be useful for clinicians and policymakers to inform patients about their prognosis and potentially implement clinical or public health strategies to reduce premature mortality.
引用
- Issa G, Shang Y, Strandberg R, et al. Cause-specific mortality in 13,099 patients with metabolic dysfunction-associated steatotic liver disease in Sweden. J Hepatol. 2025. PMID: 40139508. doi:10.1016/j.jhep.2025.03.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。